Active immunotherapy options for Alzheimer's disease

Alzheimer's Research and Therapy

Volumn 6, Issue 1, 2014, Pages

  Winblad, Bengt ^a   Graf, Ana ^b   Riviere, Marie Emmanuelle ^b   Andreasen, Niels ^c   Ryan, J Michael ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NOVARTIS PHARMA AG   (Switzerland)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AADVAC1 VACCINE; ACI 24 VACCINE; ACI 35 VACCINE; AFFITOPE VACCINE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; BAPINEUZUMAB; CAD106 VACCINE; DNA; LU AF20513 VACCINE; PEPTIDE VACCINE; SOLANEZUMAB; TAU PROTEIN; UB 311 VACCINE; UNCLASSIFIED DRUG; V950 VACCINE; VANUTIDE CRIDIFICAR; VIRUS PROTEIN;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANTIBODY RESPONSE; CLINICAL TRIAL (TOPIC); DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOTHERAPY; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 84893295027     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt237     Document Type: Review

References (56)

1. Dementia Fact Sheet No. 362. http://www.who.int/mediacentre/factsheets/ fs362/en/
2. Clinical diagnosis of alzheimer's disease: report of the NINCDS-adrda work group under the auspices of department of health and human services task force on alzheimer's disease. G McKhann, D Drachman, M Folstein, R Katzman, D Price, EM Stadlan, Neurology 1984 34 939 944 10.1212/WNL.34.7.939 6610841 (Pubitemid 14076461)
3. The global prevalence of dementia: a systematic review and metaanalysis. M Prince, R Bryce, E Albanese, A Wimo, W Ribeiro, CP Ferri, Alzheimers Dement 2013 9 63 75 10.1016/j.jalz.2012.11.007 23305823
4. The worldwide economic impact of dementia 2010. A Wimo, L Jonsson, J Bond, M Prince, B Winblad, Alzheimers Dement 2013 9 1 11 10.1016/j.jalz.2012.11. 006 23305821
5. An english translation of alzheimer's 1907 paper, 'Uber eine eigenartige Erkankung der Hirnrinde'. A Alzheimer, RA Stelzmann, HN Schnitzlein, FR Murtagh, Clin Anat 1995 8 429 431 10.1002/ca.980080612 8713166
6. The genetics of alzheimer's disease. L Bertram, RE Tanzi, Prog Mol Biol Transl Sci 2012 107 79 100 22482448
7. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. J Hardy, D Allsop, Trends Pharmacol Sci 1991 12 383 388 1763432
8. Resolving controversies on the path to Alzheimer's therapeutics. DJ Selkoe, Nat Med 2011 17 1060 1065 10.1038/nm.2460 21900936
9. Mechanisms of protein seeding in neurodegenerative diseases. LC Walker, MI Diamond, KE Duff, BT Hyman, JAMA Neurol 2013 70 304 310 10.1001/jamaneurol. 2013.1453 23599928
10. The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. C Wiessner, KH Wiederhold, AC Tissot, P Frey, S Danner, LH Jacobson, GT Jennings, R Luond, R Ortmann, J Reichwald, M Zurini, A Mir, MF Bachmann, M Staufenbiel, J Neurosci 2011 31 9323 9331 10.1523/JNEUROSCI.0293-11.2011 21697382
11. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. F Bard, C Cannon, R Barbour, RL Burke, D Games, H Grajeda, T Guido, K Hu, J Huang, K Johnson-Wood, K Khan, D Kholodenko, M Lee, I Lieberburg, R Motter, M Nguyen, F Soriano, N Vasquez, K Weiss, B Welch, P Seubert, D Schenk, T Yednock, Nat Med 2000 6 916 919 10.1038/78682 10932230 (Pubitemid 30644751)
12. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. D Schenk, R Barbour, W Dunn, G Gordon, H Grajeda, T Guido, K Hu, J Huang, K Johnson-Wood, K Khan, D Kholodenko, M Lee, Z Liao, I Lieberburg, R Motter, L Mutter, F Soriano, G Shopp, N Vasquez, C Vandevert, S Walker, M Wogulis, T Yednock, D Games, P Seubert, Nature 1999 400 173 177 10.1038/22124 10408445 (Pubitemid 29327547)
13. Passive anti-amyloid immunotherapy in alzheimer's disease: what are the most promising targets? J Moreth, C Mavoungou, K Schindowski, Immun Ageing 2013 10 18 10.1186/1742-4933-10-18 23663286
14. Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-to-moderate Alzheimer's Disease. http://www.investor.jnj.com/releasedetail.cfm?ReleaseID=698466
15. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. S Gilman, M Koller, RS Black, L Jenkins, SG Griffith, NC Fox, L Eisner, L Kirby, MB Rovira, F Forette, JM Orgogozo, Neurology 2005 64 1553 1562 10.1212/01.WNL.0000159740.16984.3C 15883316 (Pubitemid 40617691)
16. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. JM Orgogozo, S Gilman, JF Dartigues, B Laurent, M Puel, LC Kirby, P Jouanny, B Dubois, L Eisner, S Flitman, BF Michel, M Boada, A Frank, C Hock, Neurology 2003 61 46 54 10.1212/01.WNL.0000073623.84147.A8 12847155 (Pubitemid 36818745)
17. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. DH Cribbs, A Ghochikyan, V Vasilevko, M Tran, I Petrushina, N Sadzikava, D Babikyan, P Kesslak, T Kieber-Emmons, CW Cotman, MG Agadjanyan, Int Immunol 2003 15 505 514 10.1093/intimm/dxg049 12663680 (Pubitemid 36432403)
18. Neuropathology of human alzheimer disease after immunization with amyloid-beta peptide: a case report. JA Nicoll, D Wilkinson, C Holmes, P Steart, H Markham, RO Weller, Nat Med 2003 9 448 452 10.1038/nm840 12640446 (Pubitemid 36460079)
19. Increased T cell reactivity to amyloid beta protein in older humans and patients with alzheimer disease. A Monsonego, V Zota, A Karni, JI Krieger, A Bar-Or, G Bitan, AE Budson, R Sperling, DJ Selkoe, HL Weiner, J Clin Invest 2003 112 415 422 12897209 (Pubitemid 38063770)
20. Targeting beta amyloid: a clinical review of immunotherapeutic approaches in alzheimer's disease. K Lobello, JM Ryan, E Liu, G Rippon, R Black, Int J Alzheimers Dis 2012 2012 628070 22292124
21. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. B Winblad, N Andreasen, L Minthon, A Floesser, G Imbert, T Dumortier, RP Maguire, K Blennow, J Lundmark, M Staufenbiel, JM Orgogozo, A Graf, Lancet Neurol 2012 11 597 604 10.1016/S1474-4422(12)70140-0 22677258
22. Long-term administration of active immunotherapy CAD106 in phase IIa open-label extension studies in Alzheimer patients. A Graf, ME Riviere, M Farlow, N Andreasen, P Quarg, A Caputo, I Vostiar, B Winblad, JM Orgogozo, Poster at the International Conference on Alzheimer's Disease (ICAD) Vancouver, Canada 2012 23269031
23. Optimization of the treatment regimen with active Aβ immunotherapy CAD106 in Alzheimer patients. G Imbert, N Andreasen, ME Riviere, J Ros, J Moreau, J Sevigny, A Caputo, LA Finelli, B Winblad, A Graf, Poster at the International Conference on Alzheimer's Disease (ICAD) Thessaloniki, Greece 2010 23269031
24. Aβ-specific antibodies induced by active immunotherapy CAD106 engage Aβ in plasma in Alzheimer patients. B Winblad, M Farlow, K Blennow, I Vostiar, G Imbert, A Tomovic, P Quarg, ME Riviere, N Andreasen, A Graf, Poster presented at the International Conference on Alzheimer's Disease (ICAD) Paris, France 2011
25. Current phase II results from active vaccination with CAD106 in Alzheimer's disease. A Graf, Oral presentation at the International Conference on Alzheimer's Disease (ICAD) Vancouver, Canada 2012
26. Safety and tolerability of active immunotherapy CAD106 in two phase II studies in Alzheimer patients. JM Orgogozo, N Andreasen, M Farlow, A Caputo, J Moreau, C Collober, B Winblad, A Graf, Poster at the International Conference on Alzheimer's Disease (ICAD) Paris, France 2011 23269031
27. The Aβ peptide conjugate vaccine, ACC-001, generates N-terminal anti-Aβ antibodies in the absence of Aβ directed T-cell responses [abstract]. M Hagen, P Seubert, S Jacobsen, D Schenk, M Pride, R Arumugham, G Warner, G Kinney, Alzheimers Dement 2011 7 460 S461
28. Safety, tolerability, and immunogenicity of an immunotherapeutic vaccine (vanutide cridificar [ACC-001]) and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer's disease: a phase 2a, multicenter, randomized, adjuvant- and placebo-controlled, multiple-ascending-dose study [abstract P1-338]. H Arai, S Hideo, Y Tamotsu, K Lobello, P Yahong, L Enchi, K Nzeera, R Margolin, N Jackson, Y Fujimoto, Presented at the International Conference on Alzheimer's Disease (ICAD) Boston, MA, USA 2013 21808935
29. Results of the first-in-man study with the active Aβ immunotherapy CAD106 in Alzheimer patients. B Winblad, L Minthon, A Floesser, G Imbert, T Dumortier, Y He, P Maguire, M Karlsson, H Ostlund, J Lundmark, JM Orgogozo, A Graf, N Andreasen, Oral presentation at the International Conference on Alzheimer's Disease (ICAD) Vienna, Austria 2009
30. Biomarker strategy for enrichment and monitoring of biological effect in ACCTION, a phase 2 study of ACC-001 (vanutide cridificar) for Alzheimer's disease [abstract P1-357]. R Margolin, N Ketter, S Gutherie, D Deegan, L Baher, R Tschopp, K Marek, J Seibyl, G Novak, JR Streffer, C Pachai, B Wyman, K Booth, E Yuen, D Gennevois, E Lui, Presented at the International Conference on Alzheimer's Disease (ICAD) Boston, MA, USA 2013 21808935
31. Development of AFFITOPE vaccines for Alzheimer's disease (AD)-from concept to clinical testing. A Schneeberger, M Mandler, O Otawa, W Zauner, F Mattner, W Schmidt, J Nutr Health Aging 2009 13 264 267 10.1007/s12603-009-0070- 5 19262965
32. Development of AFFITOPE alzheimer vaccines: results of phase I studies with AD01 and AD02 [abstract]. M Mandler, W Schmidt, F Mattner, Alzheimers Dement 2011 7 793
33. The MimoVax vaccine: a novel alzheimer treatment strategy targeting truncated Aβ40/42 by active immunization [abstract]. M Mandler, R Santic, H Weninger, E Kopinits, W Schmidt, F Mattner, Alzheimers Dement 2009 5 114 10.1016/j.jalz.2009.01.008 19328438
34. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. A Muhs, DT Hickman, M Pihlgren, N Chuard, V Giriens, C Meerschman, I van der Auwera, F van Leuven, M Sugawara, MC Weingertner, B Bechinger, R Greferath, N Kolonko, L Nagel-Steger, D Riesner, RO Brady, A Pfeifer, C Nicolau, Proc Natl Acad Sci U S A 2007 104 9810 9815 10.1073/pnas.0703137104 17517595 (Pubitemid 47175348)
35. A novel multivalent Aβ peptide vaccine with preclinical evidence of a central immune response that generates antisera recognizing a wide range of abeta peptide species [abstract]. JM Savage, G Wu, A McCampbell, RK Wessner, M Citron, X Liang, S Hsieh, AL Wolfe, GG Kinney, BL Rosen, JJ Renger, Alzheimers Dement 2010 6 142
36. ClinicalTrials.gov. http://www.clinicaltrials.gov
37. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease. CY Wang, CL Finstad, AM Walfield, C Sia, KK Sokoll, TY Chang, XD Fang, CH Hung, B Hutter-Paier, M Windisch, Vaccine 2007 25 3041 3052 10.1016/j.vaccine.2007.01.031 17287052 (Pubitemid 46482742)
38. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. H Davtyan, A Ghochikyan, I Petrushina, A Hovakimyan, A Davtyan, A Poghosyan, AM Marleau, N Movsesyan, A Kiyatkin, S Rasool, AK Larsen, PJ Madsen, KM Wegener, DK Ditlevsen, DH Cribbs, LO Pedersen, MG Agadjanyan, J Neurosci 2013 33 4923 4934 10.1523/JNEUROSCI.4672-12.2013 23486963
39. DNA prime-protein boost increased the titer, avidity and persistence of anti-Aβ antibodies in wild-type mice. H Davtyan, M Mkrtichyan, N Movsesyan, I Petrushina, G Mamikonyan, DH Cribbs, MG Agadjanyan, A Ghochikyan, Gene Ther 2010 17 261 271 10.1038/gt.2009.140 19865176
40. DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation. D Lambracht-Washington, BX Qu, M Fu, LD Anderson Jr, O Stuve, TN Eagar, RN Rosenberg, Cell Mol Neurobiol 2011 31 867 874 10.1007/s10571-011-9680-7 21625960
41. Aβ42 gene vaccine prevents Aβ42 deposition in brain of double transgenic mice. BX Qu, Q Xiang, L Li, SA Johnston, LS Hynan, RN Rosenberg, J Neurol Sci 2007 260 204 213 10.1016/j.jns.2007.05.012 17574274 (Pubitemid 47212229)
42. Epitope-based DNA vaccine for Alzheimer's disease: translational study in macaques. CF Evans, H Davtyan, I Petrushina, A Hovakimyan, A Davtyan, D Hannaman, DH Cribbs, MG Agadjanyan, A Ghochikyan, Alzheimers Dement 2013 Epub ahead of print
43. Development of a new DNA vaccine for Alzheimer disease targeting a wide range of abeta species and amyloidogenic peptides. Y Matsumoto, N Niimi, K Kohyama, PLoS One 2013 8 75203 10.1371/journal.pone.0075203 24086465
44. Disease-modifying treatments for Alzheimer's disease. D Galimberti, E Scarpini, Ther Adv Neurol Disord 2011 4 203 216 10.1177/1756285611404470 21765871
45. Intraneuronal IgG in the central nervous system: uptake by retrograde axonal transport. RH Fabian, G Petroff, Neurology 1987 37 1780 1784 10.1212/WNL.37.11.1780 2444904 (Pubitemid 17163722)
46. Uptake of systemically administered human anticerebellar antibody by rat Purkinje cells following blood-brain barrier disruption. JE Greenlee, JB Burns, JW Rose, KA Jaeckle, S Clawson, Acta Neuropathol 1995 89 341 345 10.1007/BF00309627 7610765
47. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. EM Sigurdsson, J Alzheimers Dis 2008 15 157 168 18953105
48. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. K Yanamandra, N Kfoury, H Jiang, TE Mahan, S Ma, SE Maloney, DF Wozniak, MI Diamond, DM Holtzman, Neuron 2013 80 402 414 10.1016/j.neuron.2013.07.046 24075978
49. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. AA Asuni, A Boutajangout, D Quartermain, EM Sigurdsson, J Neurosci 2007 27 9115 9129 10.1523/JNEUROSCI.2361-07.2007 17715348 (Pubitemid 47312068)
50. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. M Boimel, N Grigoriadis, A Lourbopoulos, E Haber, O Abramsky, H Rosenmann, Exp Neurol 2010 224 472 485 10.1016/j.expneurol. 2010.05.010 20546729
51. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. A Boutajangout, D Quartermain, EM Sigurdsson, J Neurosci 2010 30 16559 16566 10.1523/JNEUROSCI.4363-10.2010 21147995
52. Tau suppression in a neurodegenerative mouse model improves memory function. K Santacruz, J Lewis, T Spires, J Paulson, L Kotilinek, M Ingelsson, A Guimaraes, M DeTure, M Ramsden, E McGowan, C Forster, M Yue, J Orne, C Janus, A Mariash, M Kuskowski, B Hyman, M Hutton, KH Ashe, Science 2005 309 476 481 10.1126/science.1113694 16020737 (Pubitemid 40994688)
53. Targeting Aβ and tau in Alzheimer's disease, an early interim report. TE Golde, L Petrucelli, J Lewis, Exp Neurol 2010 223 252 266 10.1016/j.expneurol.2009.07.035 19716367
54. Tau immunotherapy-the way how to crack the immune code of misfolded protein tau [abstract S4-02-02]. M Novak, Presented at the International Conference on Alzheimer's Disease (ICAD) Boston, MA, USA 2013 21808935
55. Efficacy and safety of a liposome-based vaccine against protein tau, assessed in Tau.P301L mice that model tauopathy. C Theunis, N Crespo-Biel, V Gafner, M Pihlgren, MP Lopez-Deber, P Reis, DT Hickman, O Adolfsson, N Chuard, DM Ndao, P Borghgraef, H Devijver, F Van Leuven, A Pfeifer, A Muhs, PLoS One 2013 8 72301 10.1371/journal.pone.0072301 23977276
56. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the alzheimer's association research roundtable workgroup. RA Sperling, CR Jack Jr, SE Black, MP Frosch, SM Greenberg, BT Hyman, P Scheltens, MC Carrillo, W Thies, MM Bednar, RS Black, HR Brashear, M Grundman, ER Siemers, HH Feldman, RJ Schindler, Alzheimers Dement 2011 7 367 385 10.1016/j.jalz.2011.05.2351 21784348